4.8 Article

NKG2A-Expressing Natural Killer Cells Dominate the Response to Autologous Lymphoblastoid Cells Infected with Epstein-Barr Virus

期刊

FRONTIERS IN IMMUNOLOGY
卷 7, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2016.00607

关键词

Epstein-Barr virus; NKG2A; NK cells; B cells; lymphoblastoid cell lines

资金

  1. NIH/NIGMS IRACDA grant
  2. Transplant and Tissue Engineering Center of Excellence
  3. NSF training grant [DGE-114740]
  4. Ruth L. Kirschstein National Research Service Award [1F31AI118469-01]
  5. NIH [DP2AI11219301, AI113130, AI115313, AI104230]

向作者/读者索取更多资源

Epstein-Barr virus (EBV) is a human.-herpesvirus that establishes latency and lifelong infection in host B cells while achieving a balance with the host immune response. When the immune system is perturbed through immunosuppression or immunodeficiency, however, these latently infected B cells can give rise to aggressive B cell lymphomas. Natural killer (NK) cells are regarded as critical in the early immune response to viral infection, but their role in controlling expansion of infected B cells is not understood. Here, we report that NK cells from healthy human donors display increased killing of autologous B lymphoblastoid cell lines (LCLs) harboring latent EBV compared to primary B cells. Coculture of NK cells with autologous EBV+ LCL identifies an NK cell population that produces IFN gamma and mobilizes the cytotoxic granule protein CD107a. Multi-parameter flow cytometry and Boolean analysis reveal that these functional cells are enriched for expression of the NK cell receptor NKG2A. Further, NKG2A(+) NK cells more efficiently lyse autologous LCL than do NKG2A(-) NK cells. More specifically, NKG2A(+) 2B4(+) CD16(-)CD57(-)NKG2C(-)NKG2D(+) cells constitute the predominant NK cell population that responds to latently infected autologous EBV+ B cells. Thus, a subset of NK cells is enhanced for the ability to recognize and eliminate autologous, EBV-infected transformed cells, laying the groundwork for harnessing this subset for therapeutic use in EBV+ malignancies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据